Opendata, web and dolomites

NSC-Reconstruct SIGNED

Novel Strategies for Cell-based Neural Reconstruction

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 NSC-Reconstruct project word cloud

Explore the words cloud of the NSC-Reconstruct project. It provides you a very rough idea of what is the project "NSC-Reconstruct" about.

treat    circuit    human    transform    structure    replacement    function    neuron    will    trauma    local    diseases    damaged    network    groups    grafting    innovative    comprising    cells    repair    pd    therapies    pluripotent    repairing    networks    tolerant    pioneering    modules    immunogenicity    cerebral    parkinson    composition    appropriate    distance    incorporating    neurological    injuries    entering    neuronal    embryonic    forming    functionally    move    groundbreaking    types    carry    neurodegenerative    patient    functional    reprogramming    ed    connections    single    starting    restoring    cns    functions    immune    situ    clinical    authenticity    cortex    minimized    stem    brain    disorder    huntington    optimization    stroke    restoration    trials    enhanced    reconstruction    grafted    science    nsc    reconstruct    area    unmet    projections    ultimately    clinically    cell    disease    disorders    pave    compositions    donor    generation   

Project "NSC-Reconstruct" data sheet

The following table provides information about the project.

Coordinator
UNIVERSITA DEGLI STUDI DI MILANO 

Organization address
address: Via Festa Del Perdono 7
city: MILANO
postcode: 20122
website: www.unimi.it

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Italy [IT]
 Total cost 8˙169˙231 €
 EC max contribution 8˙168˙495 € (100%)
 Programme 1. H2020-EU.3.1.3. (Treating and managing disease)
 Code Call H2020-SC1-2019-Single-Stage-RTD
 Funding Scheme RIA
 Starting year 2020
 Duration (year-month-day) from 2020-01-01   to  2023-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    UNIVERSITA DEGLI STUDI DI MILANO IT (MILANO) coordinator 1˙518˙495.00
2    LUNDS UNIVERSITET SE (LUND) participant 930˙000.00
3    UNIVERSITA DEGLI STUDI DI TORINO IT (TORINO) participant 780˙000.00
4    KAROLINSKA INSTITUTET SE (STOCKHOLM) participant 680˙000.00
5    THE CHANCELLOR MASTERS AND SCHOLARSOF THE UNIVERSITY OF CAMBRIDGE UK (CAMBRIDGE) participant 680˙000.00
6    UNIVERSITATSKLINIKUM BONN DE (BONN) participant 680˙000.00
7    CARDIFF UNIVERSITY UK (CARDIFF) participant 500˙000.00
8    HELMHOLTZ ZENTRUM MUENCHEN DEUTSCHES FORSCHUNGSZENTRUM FUER GESUNDHEIT UND UMWELT GMBH DE (NEUHERBERG) participant 500˙000.00
9    VIB BE (ZWIJNAARDE - GENT) participant 500˙000.00
10    KOBENHAVNS UNIVERSITET DK (KOBENHAVN) participant 400˙000.00
11    MILTENYI BIOTEC GMBH DE (BERGISH GLADBACH) participant 400˙000.00
12    LIFE AND BRAIN GMBH DE (BONN) participant 300˙000.00
13    NOVO NORDISK A/S DK (BAGSVAERD) participant 300˙000.00

Map

 Project objective

Neurodegenerative diseases and brain injuries affect large patient groups and carry large unmet clinical needs. NSC-Reconstruct will respond to these needs by developing innovative therapies based on cell replacement, cell reprogramming and circuit reconstruction that have the potential to transform how we treat a wide range of neurological diseases and disorders. In this area of clinical science European research has generated groundbreaking knowledge that has resulted in a pioneering human embryonic stem cell-derived product that is now entering clinical trials for Parkinson’s Disease (PD). In NSC-Reconstruct we will move beyond the replacement of a single neuronal type towards future cell therapies with enhanced authenticity, functions and compositions. NSC-Reconstruct will address PD as an example of disorder for which single neuron replacement has been developed. Our focus in PD will be on incorporating improved cell types and on local network reconstruction. We will also work on repairing long distance networks such as those affected in Huntington’s disease and finally in restoring the complex networks and projections of the cerebral cortex to achieve effective repair in conditions known to affect this structure, such as trauma or stroke. NSC-Reconstruct will lead to (i) the generation of neuronal types with clinically relevant functionality starting from human pluripotent stem cells or through in situ reprogramming, (ii) the optimization of donor cell composition through grafting of functional modules comprising distinct cell types capable of forming appropriate connections, (iii) the restoration of function through the reconstruction of these damaged connections and finally (iv) a greater understanding of the immunogenicity of grafted cells and how this can be minimized. Ultimately, NSC-Reconstruct will provide unique knowledge and products that will pave the way for future CNS cell replacement therapies using functionally enhanced and immune-tolerant cells.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "NSC-RECONSTRUCT" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "NSC-RECONSTRUCT" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.1.3.)

MISTRAL (2020)

Microbiome-based stratification of individuals at risk of HIV-1 acquisition, chronic clinical complications,antimicrobial drug resistance,and unresponsiveness to therapeutic HIV-1 vaccination

Read More  

HELP (2019)

Collaboration for innovation: Establishment of a pan-nematode drug development platform

Read More  

TT4CL (2019)

Clinical development of oral oleylphosphocholine as a new drug for the treatment of Old World Cutaneous Leishmaniasis

Read More